Home › Diabetic Kidney Problems › NCT05918523

A Long-Term Follow-Up Study of Participants Exposed to REACT

A Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy From Studies RMCL-002, REGEN-003, REGEN-004

Who can join

Ages 30 to 80 · All sexes

Inclusion Criteria:

* The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.

Exclusion Criteria:

* The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.

About the study

The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).

What is being tested

• Renal Autologous Cell Therapy (REACT) (biological)

Sponsor: Prokidney · Participants: 80 · Started: Dec 11, 2023

Contact the study team

• Beth Hilburger · Phone: 336-999-7031

Official record on ClinicalTrials.gov — NCT05918523

Locations in the U.S.

Conditions

• Diabetic Kidney Problems
• Chronic Kidney Disease

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.